Indication
Small Cell Lung Carcinoma
61 clinical trials
65 products
12 drugs
Clinical trial
A Phase 1/2 Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Phase I Multicenter Study of Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)Status: Active (not recruiting), Estimated PCD: 2020-12-31
Product
DurvalumabProduct
CisplatinProduct
CarboplatinProduct
TremelimumabProduct
JDQ443Clinical trial
A Phase 1, Open-label, Single-dose, Multi-center, Parallel Group Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Matched Healthy Control Participants.Status: Recruiting, Estimated PCD: 2024-06-17
Clinical trial
A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN)Status: Active (not recruiting), Estimated PCD: 2020-01-27
Product
EtoposideProduct
CBX-12Product
PemetrexedProduct
PaclitaxelClinical trial
An Open-label Phase 1 PET Imaging Trial to Investigate [89Zr]Zr-BI 764532 Biodistribution and Tumour Uptake in Patients With Small-cell Lung Carcinoma or Neuroendocrine CarcinomaStatus: Recruiting, Estimated PCD: 2026-01-18
Product
BI 764532Product
Zr-BI 764532Product
TiragolumabProduct
AtezolizumabClinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2023-08-31
Product
TrametininbProduct
DabrafenibClinical trial
A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Investigational Agents for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98)Status: Active (not recruiting), Estimated PCD: 2026-11-02
Product
MK-4830Product
Favezelimab + PembrolizumabProduct
Pembrolizumab + QuavonlimabProduct
lenvatinibProduct
durvalumabClinical trial
EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer. Prospective Cohort of Extensive Stage Small Cell Lung Cancer Patients Treated With Durvalumab Associated With Platinum-etoposide ChemotherapyStatus: Recruiting, Estimated PCD: 2027-04-16
Product
Pembrolizumab + VibostolimabClinical trial
A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2025-05-08
Product
SalineClinical trial
DAREON™-5: An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Relapsed/Refractory Neuroendocrine CarcinomasStatus: Recruiting, Estimated PCD: 2024-09-25
Product
NKT3447Product
pembrolizumabClinical trial
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)Status: Recruiting, Estimated PCD: 2027-05-04
Clinical trial
A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Orally Available CDK2 Inhibitor NKT3447 in Adults With Advanced/Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-03-01
Product
SGN-CEACAM5CClinical trial
An Open-label Phase 1 Study to Investigate SGN-CEACAM5C in Adults With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2029-03-31
Clinical trial
A Phase 1b, Multicenter, Open-label, Dose Finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of CC-90011 Given in Combination With Cisplatin and Etoposide in First Line, Extensive Stage Subjects With Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2024-06-26
Product
CC-90011Product
NivolumabClinical trial
DAREONᵀᴹ-8: A Phase I, Open-label, Dose Escalation and Expansion Trial of Repeated Intravenous Infusions of BI 764532 Combined With Standard of Care (Platinium, Etoposide, and Anti-PD-L1) in Patients With Extensive-stage Small Cell Lung CarcinomaStatus: Recruiting, Estimated PCD: 2025-08-20
Clinical trial
DAREON™-9: A Phase Ib Open-label Dose Escalation and Dose Confirmation Safety Study of Intravenous BI 764532 in Combination With Topotecan for the Treatment of Patients With Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-10-27
Product
TopotecanProduct
TarlatamabClinical trial
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)Status: Recruiting, Estimated PCD: 2024-10-22
Product
PembrolizumabProduct
CRS Mitigation StrategiesClinical trial
A Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of BI 764532 Combined With Ezabenlimab in Patients With Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3Status: Recruiting, Estimated PCD: 2025-02-28
Product
EzabenlimabClinical trial
Phase III Clinical Study of AL8326 Tablets in Patients With Advanced or Recurrent Small Cell Lung Cancer After at Least Prior Second-line TreatmentStatus: Recruiting, Estimated PCD: 2028-07-01
Product
placeboProduct
AL8326Product
XmAb20717Clinical trial
A First-In-human Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of BI 764532 Administered by Parenteral Route in Patients With Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3Status: Recruiting, Estimated PCD: 2024-09-02
Clinical trial
An Open-Label, Multicenter, Phase 2 Study of the Safety and Efficacy of KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer (SCLC)Status: Terminated, Estimated PCD: 2022-08-26
Clinical trial
A Phase IIIB, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer - MAURISStatus: Completed, Estimated PCD: 2023-07-13
Clinical trial
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid TumorsStatus: Completed, Estimated PCD: 2022-06-01
Product
KRT-232Clinical trial
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)Status: Completed, Estimated PCD: 2023-02-16
Product
XmAb®22841Clinical trial
A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung CancerStatus: Completed, Estimated PCD: 2018-04-24
Clinical trial
An Open Label, Multicenter Study of First-Line Durvalumab Plus Platinum-Based Chemotherapy in Chinese Patients With Extensive Stage Small-Cell Lung Cancer (Oriental)Status: Completed, Estimated PCD: 2023-03-30
Product
PlaceboProduct
paclitaxelClinical trial
A Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above ChemotherapiesStatus: Completed, Estimated PCD: 2023-01-31
Product
IBI318Clinical trial
A Phase IIIB, Single Arm Study, of Durvalumab in Combination With Platinum-Etoposide for Untreated Patients With Extensive-Stage Small Cell Lung Cancer Reflecting Real World Clinical Practice in Spain (CANTABRICO).Status: Completed, Estimated PCD: 2023-06-21
Clinical trial
Phase I Clinical Trial of M6620 (VX-970, Berzosertib) in Combination With the Topoisomerase I Inhibitor Irinotecan in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-03-07
Product
BerzosertibProduct
IrinotecanClinical trial
Immuno-PET Imaging of Neuroendocrine Tumors Using 89Zr-DFO-SC16.56, a DLL3-targeting Monoclonal AntibodyStatus: Recruiting, Estimated PCD: 2026-06-11
Product
89Zr-DFO-SC16.56Product
SC16.56Clinical trial
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2022-06-22
Product
CediranibClinical trial
A Multicenter Phase II Trial of Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in Homologous Recombination Deficiency (HRD) Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)Status: Not yet recruiting, Estimated PCD: 2026-09-01
Drug
AN0025Product
OlaparibClinical trial
Phase I/II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Pembrolizumab in Patients With Relapsed Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2023-09-30
Drug
LurbinectedinClinical trial
Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung CancerStatus: Not yet recruiting, Estimated PCD: 2026-05-31
Drug
AdebrelimabProduct
Etoposide + CarboplatinClinical trial
A Phase I Study of Weekly Doxorubicin and Oral Topotecan for Patients With Relapsed or Refractory Small Cell Lung Cancer (SCLC)Status: Completed, Estimated PCD: 2018-02-01
Product
DoxorubicinClinical trial
Evaluating the Safety and Efficacy of Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)Status: Recruiting, Estimated PCD: 2025-04-30
Product
Mycophenolate MofetilDrug
AllopurinolDrug
IrinotecanClinical trial
A Randomized, Multi-Cohort Phase II Trial of Temozolomide and Atezolizumab as Second or Third Line Treatment for Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2024-12-31
Drug
AtezolizumabProduct
TMZClinical trial
A Phase I-II Trial of Combined PKCι and mTOR Inhibition for Patients With Advanced or Recurrent Lung Cancer (NSCLC and SCLC) Without Standard Treatment OptionsStatus: Completed, Estimated PCD: 2023-04-24
Product
AuranofinProduct
SirolimusClinical trial
A Phase Ⅱ Exploratory Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy as First-Line Treatment for Extensive-Stage Oligometastatic Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2026-06-30
Product
Carboplatin/CisplatinClinical trial
Endobronchial Ultrasound Transbronchial Needle Guided Interstitial Photodynamic Therapy for Palliation of Locally Advanced Lung Cancer and Advanced Cancers Obstructing the Airway -Phase I/IIStatus: Recruiting, Estimated PCD: 2030-02-12
Product
PorfimerClinical trial
Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or Fewer Brain Metastases From Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2028-07-01
Product
MemantineClinical trial
Biology of Young Lung Cancer Study: The YOUNG LUNG StudyStatus: Recruiting, Estimated PCD: 2027-08-01
Product
Data and Specimen CollectionClinical trial
Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of M6620 (VX-970, Berzosertib) When Combined With Whole Brain Radiotherapy (WBRT) in Patients With Brain Metastases From Lung CancerStatus: Active (not recruiting), Estimated PCD: 2021-08-23
Clinical trial
A Phase I Study of Olaparib and Low Dose Thoracic Radiotherapy for Extensive Stage Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase I/II Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor in Small Cell CancersStatus: Active (not recruiting), Estimated PCD: 2021-02-24
Product
VX-970Clinical trial
Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV InfectionStatus: Active (not recruiting), Estimated PCD: 2025-11-02
Product
CabozantinibDrug
T-VECClinical trial
A Phase I Study of Durvalumab (MEDI4736) Plus Tremelimumab in Combination With Platinum-based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer and Performance Status 2Status: Terminated, Estimated PCD: 2021-12-15
Product
Durvalumab + TremelimumabClinical trial
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung CancersStatus: Recruiting, Estimated PCD: 2027-12-31
Drug
ADI-PEG 20Drug
GemcitabineDrug
DocetaxelClinical trial
Niraparib (PARP Inhibitor) Plus Dostarlimab (Anti-PD1) for Small Cell Lung Cancer (SCLC) and Other High-Grade Neuroendocrine Carcinomas (NEC)Status: Active (not recruiting), Estimated PCD: 2025-05-30
Clinical trial
A Phase II, Multi-Cohort Trial of Combination Nivolumab and Temozolomide in Recurrent/Refractory Small-Cell Lung Cancer and Advanced Neuroendocrine TumorsStatus: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
Phase II Pilot Study of Subsequent Line Gemcitabine and Nivolumab for Advanced SCLCStatus: Terminated, Estimated PCD: 2020-10-07
Clinical trial
Phase 1b/II Trial of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies (Phase Ib) and Small Cell Lung Cancer Patients (Phase II) Who Have Progressed on Prior Platinum-based ChemotherapyStatus: Completed, Estimated PCD: 2018-12-31
Drug
CarfilzomibDrug
mFOLFOXIRIClinical trial
BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients With Advanced Solid Tumors, Phase I Studies With Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)Status: Active (not recruiting), Estimated PCD: 2025-02-15
Product
ElimusertibClinical trial
An Open-label, Phase II, Multi-cohort, 2-stage Trial to Evaluate the Efficacy and Safety of Regorafenib in Combination With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Pretreated Solid CancersStatus: Withdrawn, Estimated PCD: 2025-04-30
Product
RegorafenibClinical trial
Phase II Clinical Trial of Durvalumab (MEDI4736) and Lurbinectedin in Patients With Relapsed Extensive Stage Small Cell Lung Cancer Previously Treated With Chemotherapy and ImmunotherapyStatus: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Phase 2 Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2027-08-01
Product
OnvansertibClinical trial
Phased Avelumab Combined With Chemotherapy as First-line Treatment for Patients With Advanced Small-cell Lung Cancer (SCLC)Status: Active (not recruiting), Estimated PCD: 2022-03-30
Product
AvelumabClinical trial
Molecular Landscape Analysis and Clinical Implications for SCLCStatus: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
Administration of T Cells Expressing a 2nd Generation GD2 Chimeric Antigen Receptor, IL-15, and iCaspase9 Safety Switch in Subjects With Lung CancerStatus: Recruiting, Estimated PCD: 2025-02-15
Product
iC9.GD2.CAR.IL-15 T InfusionClinical trial
FASTing-like Approach to Improve the Efficacy of Maintenance IMMunotherapy in Extensive-stage Small Cell Lung Cancer Patients Not Progressing on Chemoimmunotherapy Induction: the FASTIMMUNE TrialStatus: Not yet recruiting, Estimated PCD: 2025-01-01